Amgen Inc. stock (US0311621009): Weight-loss drug data and guidance update keep investors on alert

Amgen Inc. has updated investors with new data on its experimental obesity drug and reaffirmed its 2025 guidance at a recent investor event, while the stock has been volatile amid intense weight-loss competition. What drives the story behind the shares?

Amgen Inc. has moved back into the spotlight after presenting new clinical data on its experimental obesity drug MariTide and updating its 2025 financial outlook at a recent investor meeting, while investors weighed the implications for the fiercely contested weight-loss market, according to information from Amgen’s investor materials and recent coverage by major financial media in May 2025.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amgen
• Sector/industry: Biopharmaceuticals
• Headquarters/country: Thousand Oaks, California, USA
• Core markets: United States, Europe and other global pharmaceutical markets
• Key revenue drivers: Biologic therapies in oncology, inflammation, bone health and cardiovascular disease
• Home exchange/listing venue: Nasdaq (ticker: AMGN)
• Trading currency: USD

Amgen Inc.: core business model

Amgen focuses on discovering, developing and commercializing innovative human therapeutics, with a strong emphasis on biologic drugs derived from advanced biotechnology platforms. The company’s portfolio includes treatments for serious illnesses such as cancer, inflammatory disorders and cardiovascular disease, reflecting a strategy of targeting high unmet medical need.

The group generates most of its revenue from a relatively concentrated set of blockbuster products and established biologics that are marketed globally, especially in the United States and Europe. Amgen also runs a biosimilars franchise, offering lower-cost versions of reference biologic therapies, which provides diversification but exposes the firm to pricing and competitive pressures.

In its 2024 annual report published in February 2025, Amgen highlighted ongoing investment in research and development focused on oncology, inflammation, obesity and cardiovascular disease, underlining that R&D spending remains a core pillar of its long-term growth strategy, according to the company’s regulatory filings as of February 2025.

Main revenue and product drivers for Amgen Inc.

Amgen’s revenue base is anchored by key therapies in oncology and inflammation, including products for multiple myeloma and other cancers, as well as treatments for autoimmune diseases. These medicines typically command premium pricing but face increasing competition from rival biologics and biosimilars, which can gradually erode volumes and margins over time.

The company has also built a meaningful presence in bone health and cardiovascular disease, with therapies aimed at reducing fracture risk and lowering low-density lipoprotein cholesterol in high-risk patients. These drugs serve large, chronic patient populations and can provide stable revenue streams when backed by robust clinical data and payer support.

Beyond its established portfolio, Amgen is investing in next-generation modalities, including antibody-based therapies and other biologic platforms, designed to address complex disease pathways. Management has repeatedly noted in earnings commentary that success in these newer programs is important to offset declines in older products, according to Amgen’s quarterly communications and conference call remarks as of 2024 and early 2025.

Obesity pipeline and recent investor focus

Investor attention around Amgen intensified after the company released updated data on its obesity pipeline, including the injectable candidate often referred to as MariTide, at a medical meeting in 2025. The company presented additional efficacy and safety results that suggested meaningful weight loss in treated patients, though the precise magnitude and duration of effect remain key areas of scrutiny for analysts and investors following the broader weight-loss drug race.

Amgen has framed its obesity program as a potential long-term growth driver if late-stage trials confirm the early findings and regulators ultimately approve the therapy. Management has emphasized the need to balance efficacy, safety, dosing convenience and manufacturing scalability, especially given the intense competition from GLP-1–based treatments already on the market, according to Amgen’s presentations and Q&A sessions with investors as of 2025.

At a dedicated investor event in 2025, Amgen also discussed the potential for combination treatment approaches and differentiated mechanisms targeting metabolic pathways, positioning its obesity pipeline as complementary to existing standards of care rather than a like-for-like copy. This positioning aims to carve out a distinct niche in an increasingly crowded therapeutic landscape dominated by larger players in diabetes and obesity medicines.

Financial performance and guidance context

In its results for full year 2024, published in February 2025, Amgen reported an increase in total revenue compared with 2023, supported by contributions from newer products and the integration of acquired assets, according to the company’s annual filing and earnings release as of February 2025. The report indicated that operating income and adjusted earnings per share benefited from revenue growth and cost discipline, although higher R&D spending partly offset these gains.

For 2025, management issued guidance that called for modest revenue growth and a focus on operating margin stability, while signaling continued investment in the pipeline. The company subsequently reaffirmed this 2025 outlook at a later investor meeting in 2025, noting that demand for key products was tracking broadly in line with internal plans, according to Amgen’s investor presentation materials and commentary made available in 2025.

Investors have paid close attention to how Amgen balances shareholder returns, including dividends and share repurchases, with the need to fund its late-stage pipeline. The company has a history of returning cash to shareholders through a regular dividend and buybacks, but management has also indicated that capital allocation decisions will reflect the scale of ongoing clinical programs and potential business development opportunities, based on statements in company communications as of 2024 and 2025.

Industry trends and competitive position

The biopharmaceutical industry has seen growing emphasis on specialty medicines and high-value biologics, areas where Amgen already has a significant presence. However, the sector is also experiencing tightening cost controls by healthcare systems and insurers, which are pushing back on pricing and encouraging the use of lower-cost biosimilars where available, particularly in the United States and Europe.

Amgen competes with other large biopharma companies across oncology, inflammation and cardiovascular disease, and increasingly in obesity. The weight-loss drug segment has become one of the most closely watched markets globally, with expectations of multi-billion-dollar annual sales industry-wide. In this environment, any new clinical data from Amgen’s obesity program is quickly scrutinized as investors compare efficacy, safety and commercial potential with established GLP-1 and related therapies.

At the same time, the biosimilars business exposes Amgen to competitive dynamics on both sides: the company sells its own biosimilars while also facing biosimilar competition to some of its established biologics. This dual role requires careful portfolio management to sustain margins, especially in the US market, where pricing pressure can be intense and payers actively negotiate discounts.

Why Amgen Inc. matters for US investors

For US investors, Amgen represents a large-cap biopharma name listed on Nasdaq, with meaningful weight in major US equity indices and healthcare sector benchmarks. Movements in Amgen’s stock can therefore influence healthcare-focused exchange-traded funds and mutual funds, making its news flow relevant beyond individual shareholders.

The company’s exposure to the US healthcare system, including Medicare and commercial insurers, means that changes in US drug-pricing policy, reimbursement frameworks or regulatory requirements can have a direct impact on its profitability. Accordingly, policy debates in Washington around prescription drug costs are often reflected in investor sentiment toward Amgen and its peers, particularly when proposals address biologics and specialty drugs.

US-based investors also watch Amgen’s capital allocation decisions closely, because dividends and share repurchases can play a significant role in total return strategies. The stock’s performance may be influenced both by fundamental developments like clinical data and by broader factors such as interest-rate expectations and sector rotation within US equity markets, where defensive healthcare names can sometimes be viewed as relative safe havens.

Conclusion

Amgen Inc. is navigating a complex landscape of maturing biologic franchises, biosimilar competition and rising expectations around its obesity pipeline, while aiming to deliver steady financial performance and maintain shareholder returns. Recent data updates and guidance reaffirmations underline management’s focus on pipeline execution and disciplined capital allocation, even as the competitive environment in weight loss and other therapeutic areas intensifies. For investors following large US biopharma stocks, Amgen’s progress in translating its research investments into durable revenue streams remains a central theme to watch over the coming years.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.